Search results
Results from the WOW.Com Content Network
Possible senolytic agents are under preliminary research, including some which are in early-stage human trials. [6] [7] [clarification needed] The majority of candidate senolytic compounds are repurposed anti-cancer molecules, such as the chemotherapeutic drug dasatinib and the experimental small molecule navitoclax.
Senotherapeutics include emerging senolytic/senoptotic small molecules that specifically induce cell death in senescent cells [2] and agents that inhibit the pro-inflammatory senescent secretome. [3] Senescent cells can be targeted for immune clearance, but an ageing immune system likely impairs senescent cell clearance leading to their ...
ABT-737 is a small molecule drug that inhibits Bcl-2 and Bcl-xL, two members of the Bcl-2 family of evolutionarily-conserved proteins that share Bcl-2 Homology (BH) domains. First developed as a potential cancer chemotherapy, [1] it was subsequently identified as a senolytic (a drug that selectively induces cell death in senescent cells). [2]
This is a list of chemotherapeutic agents, also known as cytotoxic agents or cytostatic drugs, that are known to be of use in chemotherapy for cancer.This list is organized by type of agent, although the subsections are not necessarily definitive and are subject to revision.
This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.
Osteoporosis, including drug- and cancer-related osteoporosis, giant cell tumour of bone and hypercalcaemia of malignancies: Hypercholesterolaemia, cataract, urinary retention, hypocalcaemia, osteonecrosis of the jaw and anaphylaxis. Gemtuzumab ozogamicin: IV: CD33 antibody that induces apoptosis of the tagged cell. Acute myeloid leukaemia
Chemical substances that (a) have been shown in laboratory research to increase longevity or retard senescence or some aspects thereof, (b) are proposed but not proven to do so or (c) may be promoted as such.
Chimeric antigen receptor T cells have been proposed as an alternative means to senolytic drugs for the elimination of senescent cells. [64] Urokinase receptors have been found to be highly expressed on senescent cells, leading researchers to use chimeric antigen receptor T cells to eliminate senescent cells in mice.